Literature DB >> 8818693

Apoptosis occurs independently of bcl-2 and p53 over-expression in non-small cell lung carcinoma.

A J O'Neill1, M J Staunton, E F Gaffney.   

Abstract

Certain oncogenes and tumour suppressor genes are known to modulate apoptosis. To investigate whether overexpressed bcl-2 and abnormally stabilized p53 are associated with reduced apoptosis in paraffin sections of non-small cell lung carcinoma, apoptotic, mitotic, and Ki-67 labelling indices were determined and correlated with bcl-2 and p53 immunoreactivity in 54 squamous cell carcinomas and 22 adenocarcinomas. Nineteen squamous cell carcinomas (35.2%) showed over-expression of bcl-2, but all 22 adenocarcinomas were bcl-2 negative. Thirty-seven squamous cell carcinomas (68.5%) and 13 adenocarcinomas (59.1%) showed p53 over-expression. Apoptotic tumour cells were identified among p53 positive and bcl-2 positive tumour cells. There was a significant linear correlation between apoptotic indices and mitotic indices. bcl-2 over-expression and p53 over-expression were not associated with attenuated apoptosis, or altered mitotic or Ki-67 labelling indices in either tumour type. Neither bcl-2 nor p53 was of prognostic significance. These results suggest that apoptosis in non-small cell lung carcinoma occurs independently, and is not modulated primarily by, bcl-2 or p53. It is likely that the effects on apoptosis of bcl-2 and p53 are countered by those of other oncogene products and/or additional factors that regulate apoptosis in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818693     DOI: 10.1046/j.1365-2559.1996.d01-478.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?

Authors:  G Cox; R A Walker; S Muller; K R Abrams; W P Steward; K J O'Byrne
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Apoptosis in cancer: archaeology, functional relevance and exploitation in novel treatment strategies.

Authors:  E F Gaffney
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

Review 3.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

4.  Abl expression, tumour grade, and apoptosis in chondrosarcoma.

Authors:  M O'Donovan; J M Russell; J J O'Leary; J A Gillan; M P Lawler; E F Gaffney
Journal:  Mol Pathol       Date:  1999-12

5.  The expression of c-myc, bcl-2 and p53 proteins in adenocarcinomas of lung.

Authors:  Jinyoung Yoo; Ji Han Jung; Hyun Joo Choi; Seok Jin Kang; Chang Suk Kang
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

6.  Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.

Authors:  M E McMenamin; A J O'Neill; E F Gaffney
Journal:  Mol Pathol       Date:  1997-10

7.  Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis.

Authors:  Jinyoung Yoo; Ji Han Jung; Myung A Lee; Kyung Jin Seo; Byoung Yong Shim; Sung Hwan Kim; Deog Gon Cho; Myeong Im Ahn; Chi Hong Kim; Kyu Do Cho; Seok Jin Kang; Hoon Kyo Kim
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

Review 8.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis.

Authors:  B Martin; M Paesmans; T Berghmans; F Branle; L Ghisdal; C Mascaux; A-P Meert; E Steels; F Vallot; J-M Verdebout; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

9.  Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review.

Authors:  Jie Zhang; Shengfei Wang; Lei Wang; Rui Wang; Sufeng Chen; Bin Pan; Yihua Sun; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2015-11-18       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.